

ImpediMed Limited 1/50 Parker Court Pinkenba, QLD, 4008 Australia

E: investorrelations@impedimed.com

W: impedimed.com

29 August 2024

Companies Announcements Office Australian Securities Exchange

## Appendix 4E - Financial year ended 30 June 2024

ImpediMed Limited (ASX: IPD) provides the attached Appendix 4E – Preliminary Final Report for the financial year ended 30 June 2024.

Approved for release by the Board of ImpediMed Limited.

For more information, contact Leanne Ralph, Company Secretary, at leanne.ralph@bellev.com.au

## Appendix 4E ImpediMed Limited ABN 65 089 705 144 Preliminary Final Report

1 Reporting period: Year ended 30 June 2024
Prior Corresponding Reporting Period: Year ended 30 June 2023

2 Results for announcement to the market

Net tangible assets per security

Net tangible assets per security

		% change		\$000
Revenue	down	-9%	to	10,319
(Loss) from ordinary activities after tax attributable to members	down	-4%	to	-19,790
(Loss) for the period attributable to members	down	-4%	to	-19,790
<b>Dividends</b> There were no dividends declared and paid d There were no dividends proposed and not ye				
Dividend Record Date	Not applicable			

Additional Appendix 4E disclosure requirements are included in the 30 June 2024 Annual Financial Statements lodged with this document. The report is based on the 30 June 2024 Annual Financial Statements which are audited by Ernst & Young and are not subject to dispute, modification, or qualification. The information contained in this document should be read in conjunction with the ImpediMed Limited Annual Financial Report for the year ended 30 June 2024 and any public announcements made by ImpediMed Limited and its controlled entities during the year.

30-June-2024

1.22 cents

30-June-2023

2.28 cents